Cardinal Health restructures
This article was originally published in The Gray Sheet
Executive Summary
Dublin, Ohio-based firm is consolidating into two core businesses and cutting 600 jobs. The new organization, announced July 8, will consist of a Healthcare Supply Chain Services segment, which as a pharmaceutical/medical product distributor generates annual sales of over $80 billion, and a Clinical and Medical Products segment, with annual revenue of $5 billion. The latter group will include Cardinal Health's Alaris infusion pumps, Avea respirators, Pyxis medication dispensing systems, surgical gowns, gloves and other medical products. The firm says that over the next year it will evaluate the fit of a third business group, which includes its Tecomet orthopedic implant manufacturing services unit and Medsystems enteral devices and airway management products. The cost of the restructuring is estimated at $63 million in fiscal year 2009, which began July 1
You may also be interested in...
Cardinal spin-off?
Cardinal Health is weighing the possibility of spinning off its $5.6 billion clinical and medical products business as a separate, publicly traded company, the firm said Aug. 7. Last month, Cardinal consolidated its two major business activities of health care product sales and its $80 billion distributor operation into two distinct business units and cut 600 jobs (1"The Gray Sheet" July 21, 2008, In Brief). The clinical and medical products business includes Alaris infusion pumps, Avea respirators, Pyxis medication dispensing system, surgical gowns and gloves
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.